Original article

Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

Antonio Rivero\textsuperscript{a}, José Antonio Pérez-Molina\textsuperscript{b}, Antonio Javier Blasco\textsuperscript{c,d}, José Ramón Arribas\textsuperscript{d}, Víctor Asensi\textsuperscript{e}, Manuel Crespo\textsuperscript{f}, Pere Domingo\textsuperscript{g}, José Antonio Iribarren\textsuperscript{h}, Pablo Lázaro\textsuperscript{c}, José López-Aldeguer\textsuperscript{i}, Fernando Lozano\textsuperscript{j}, Esteban Martínez\textsuperscript{k}, Santiago Moreno\textsuperscript{l}, Rosario Palacios\textsuperscript{m}, Juan Antonio Pineda\textsuperscript{j}, Federico Pulido\textsuperscript{n}, Rafael Rubio\textsuperscript{n}, Jesús Santos\textsuperscript{o}, Javier de la Torre\textsuperscript{p}, Montserrat Tusell\textsuperscript{q}, Josep M. Gatell\textsuperscript{k}

\textsuperscript{a} Unidad de Gestión Clínica de Enfermedades Infecciosas, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba, Spain
\textsuperscript{b} Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
\textsuperscript{c} Independent Health Services Researcher, Madrid, Spain
\textsuperscript{d} Servicio de Medicina Interna, Unidad de VIH, IDIPAZ, Hospital Universitario La Paz, Madrid, Spain
\textsuperscript{e} Unidad de Enfermedades Infecciosas-VIH, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain
\textsuperscript{f} Complejo Hospitalario Universitario de Vigo, Vigo, Spain
\textsuperscript{g} Hospitals Universitarios Arnau de Vilanova & Santa María, Universitat de Lleida, Institut de Recerca Biomèdica (IRB) de Lleida, Lleida, Spain
\textsuperscript{h} Servicio de Enfermedades Infecciosas, Hospital Universitario Donostia, San Sebastián, Spain
\textsuperscript{i} Servicio de Medicina Interna y Unidad de Enfermedades Infecciosas Hospital Universitario La Fe, IISLaFe, Valencia, Spain
\textsuperscript{j} Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, Spain
\textsuperscript{k} Servicio de Enfermedades Infecciosas, Hospital Clinic-IDIBAPS, Universitat de Barcelona, Barcelona, Spain
\textsuperscript{l} Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Universidad de Alcalá de Henares, Instituto de Investigación Sanitaria Ramón y Cajal (IRYCS), Madrid, Spain
\textsuperscript{m} Unidad de Enfermedades Infecciosas, Hospital Virgen de la Victoria, Málaga, Spain
\textsuperscript{n} Unidad de Enfermedades Infecciosas, Hospital Málaga, Málaga, Spain
\textsuperscript{o} Unidad de Enfermedades Infecciosas, Hospital Universitario Virgen de la Victoria, Málaga. Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain
\textsuperscript{p} Grupo de Enfermedades Infecciosas de la Unidad de Medicina Interna, Hospital Costa del Sol, Marbella, Málaga, Spain
\textsuperscript{q} Servicio de Farmacia, Hospital Clinic, Barcelona, Spain

\textbf{A R T I C L E   I N F O}

Article history:
Received 24 February 2017
Accepted 11 April 2017
Available online xxx

Keywords:
Costs
Efficacy
Efficiency
HIV
AIDS
Antiretroviral therapy

\textbf{A B S T R A C T}

\textit{Introduction:} GESIDA and the Spanish National AIDS Plan panel of experts have recommended preferred (PR), alternative (AR) and other regimens (OR) for antiretroviral therapy (ART) as initial therapy in HIV-infected patients for 2017. The objective of this study was to evaluate the costs and the efficiency of initiating treatment with PR and AR.

\textit{Methods:} Economic assessment of costs and efficiency (cost-efficacy) based on decision tree analyses. Efficacy was defined as the probability of reporting a viral load <50 copies/mL at week 48, in an intention-to-treat analysis. Cost of initiating treatment with an ART regimen was defined as the costs of ART and its consequences (adverse effects, changes of ART regimen and drug resistance studies) during the first 48 weeks. The payer perspective (National Health System) was applied considering only differential direct costs: ART (official prices), management of adverse effects, resistance studies and HLA B*5701 screening.

The setting was Spain and the costs correspond to those of 2017. A deterministic sensitivity analysis was conducted, building three scenarios for each regimen: base case, most favourable and least favourable.

\textit{Results:} In the base case scenario, the cost of initiating treatment ranged from 6882 euro for TFV/FTC/TPV (AR) to 10,904 euros for TFV/FTC + RAL (PR). The efficacy varied from 0.82 for TFV/FTC + DRV (AR) to 0.92 for TAF/FTC/EVG/COBI (PR). The efficiency, in terms of cost-efficacy, ranged from 7923 to 12,765 euros per responder at 48 weeks, for ABC/3TC/DTG (PR) and TFV/FTC + RAL (PR), respectively.

\textit{Conclusion:} Considering ART official prices, the most efficient regimen was ABC/3TC/DTG (PR), followed by TFV/FTC/TPV (AR) and TAF/FTC/EVG/COBI (PR).

© 2017 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

* Corresponding author.
E-mail address: antonioblasco@hotmail.com (A.J. Blasco).

http://dx.doi.org/10.1016/j.eimc.2017.04.002
0213-005X © 2017 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.
Análisis de costes y de coste/eficacia de las pautas recomendadas por GESIDA/Plan Nacional sobre el Sida en 2017 para el tratamiento antirretroviral inicial en adultos infectados por el VIH

RESUMEN

Introducción: El panel de expertos de GESIDA/Plan Nacional del Sida ha recomendado pautas preferentes (PP), pautas alternativas (PA) y otras pautas (OP) para el tratamiento antirretroviral (TARV) como terapia de inicio en pacientes infectados por VIH para 2017. El objetivo de este estudio es evaluar los costes y la eficiencia de iniciar tratamiento con PP y PA.

Métodos: Evaluación económica de costes y eficiencia (coste/eficacia) mediante construcción de árboles de decisión. Se definió eficacia como la probabilidad de tener carga viral < 50 copias/mL en la semana 48 en análisis por intención de tratar. Se definió coste de iniciar tratamiento con una pauta como los costes del TARV y de todas sus consecuencias (efectos adversos, cambios de pauta y estudio de resistencias) que se producen en las siguientes 48 semanas. Se utilizó la perspectiva del Sistema Nacional de Salud, considerando solo costes directos diferenciales: TARV (a precio oficial), manejo de efectos adversos, estudios de resistencias y determinación de HLA B*5701. El ámbito es España, con costes de 2017. Se realizó un análisis de sensibilidad determinista construyendo 3 escenarios para cada pauta: basal, más favorable y más desfavorable.

Resultados: En el escenario basal, los costes de iniciar tratamiento oscilaron entre 6.882 euros para TFV/FTC/RPV (PA) y 10.904 euros para TFV/FTC+RAL (PP). La eficacia osciló entre 0.82 para TFV/FTC+DRV/p (PA) y 0.92 para TAF/FTC/EVG/CObI (PP). La eficacia, en términos de coste/eficacia, osciló entre 7.923 y 12.765 euros por respondedor a las 48 semanas, para ABC/3TC/DTG (PP) y TFV/FTC+RAL (PP), respectivamente.

Conclusión: Considerando el precio oficial del TARV, la pauta más eficiente fue ABC/3TC/DTG (PP), seguida de TFV/FTC/DRV/p (PA) y TAF/FTC/EVG/CObI (PP).

© 2017 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Todos los derechos reservados.
reproduces the regimen’s characteristics in terms of efficacy, AE, and reasons for withdrawal (Table 1 and Fig. 1).

Sources providing data on efficacy, AE, and withdrawals

The SC provided the studies reporting the RCT data potentially useful for the economic assessment of the different regimens evaluated. To be included, the RCTs had to: (1) assess at least one of the regimens under evaluation; (2) provide or allow the calculation of the proportion of patients with undetectable viral loads (<50 copies/mL) at 48 weeks; (3) follow patients for at least 48 weeks; (4) report patient withdrawal rates and reasons; and (5) report AE. Studies found eligible were included as source of scientific evidence for the model.

Sources of information in the absence of scientific evidence: the use of expert opinion

When scientific evidence on certain needed variables was not available, the SC expert opinion was used. Two investigators (PL and AJB) elaborated data collection sheets for the variables of interest. These sheets were then sent to each expert. To assure that the experts’ responses were independent from each other, contact among SC members was not allowed. Regarding continuous variables (e.g., duration in days of an itching episode, or number of visits to a specialist in case of renal failure), the mean of the experts’ estimates was calculated. For dichotomous variables (e.g., a serious/moderate AE is or is not ART-related, or is chronic or with isolated occurrence) the majority opinion was chosen. The resulting summary estimates were reviewed and approved by all SC members.

Efficacy definition and measurement

Efficacy was defined as the quotient of the number of patients with undetectable viral load at week 48 post-ART (i.e., responders) (numerator) and the number of patients initiated on ART (denominator). Efficacy was estimated based on an intention-to-treat analysis of the exposed (“Intent-to-treat exposed” [ITT-E]) and missing or incomplete follow-ups were designated as failures.
Definition and calculation of costs

Based on a payer’s perspective, this study considers only direct costs, i.e., the use of NHS resources. Within these costs, however, only differential costs are taken into account, i.e., non-identical costs across all regimens under study: ART, AE management, genotypic study of drug resistance, and HLA B*5701 testing. Direct costs were calculated multiplying the amount of resources used by the unit cost of each resource. The cost of initiating a regimen comprises the cost of ART and all the consequences (e.g., AE or need to switch regimens) incurred in 48 weeks due to the decision of initiating ART with that regimen.

Use of resources

ART

Patients completing treatment during the trial are assigned the costs of 48 weeks of the initial regimen. For those who do not complete the treatment, it was assumed that the initial regimen was discontinued at 24 weeks, on average. Thus, they are assigned the costs of 24 weeks of the initial regimen plus the costs of 24 weeks of the substitution regimen. Each substitution regimen was chosen based on the reason for discontinuation of the initial regimen, according to the opinion of the experts (Table 2).

AE management

AE were defined as those effects identified by the RCT as ART-related. When the RCT reported a list of AE without identifying the ART-related ones, the SC opinion was applied. Since RCTs usually report AE occurring in over 2% of patients under the treatments assessed, only these AE were considered. The AE were classified into chronic and isolated according to expert opinion. Chronic AE are those that last as long as the treatment (e.g., dyslipidemia), whereas isolated AE are those occurring with a limited duration in time (e.g., skin rash).

The resources considered for the management of AE have been: drug treatment, emergency room visits, additional visits to the HIV specialist and other specialists, diagnostic tests, and hospital admissions. To the patients completing treatment during the trial, the corresponding costs of managing the AE occurring within the 48 weeks of their initial regimen were assigned. For those who do not complete the treatment, and following the aforementioned assumptions, the costs of 24 weeks of AE management related to the initial regimen and 24 weeks of AE management related to the substitution regimen were assigned (Table 2). Further, because chronic AE were assumed to occur for half of ART duration on average, the cost allocated for chronic AE management corresponds to half the period the patient received the corresponding ART. Compared to the 2013 study, there were no new AE to be considered, thus, the use of resources is that estimated by the SC in the 2013 study.20

Genotypic study of drug resistance and HLA B*5701 testing

Genotypic studies of drug resistance considered as differential costs include: (1) conventional drug resistance study (in case of virologic failure); and (2) integrase resistance study (when virologic failure occurs in a regimen containing an integrase inhibitor such as raltegravir [RAL] or elvitegravir [EVG]). When a regimen includes abacavir (ABC), HLA B*5701 testing was considered before initiating treatment.

Estimation of the unit costs of resources considered

ART

The cost of each ART was calculated according to the costs of the drugs involved. In the case of Spain, this means that regimen costs were calculated based on the laboratory sale price (LSP) plus 4% VAT minus the 7.5% reduction required by the Spanish government as one of the extraordinary measures to reduce public deficit.25 Specifically, the following drugs were assigned the following prices: (1) the ABC, lamivudine (3TC) and dolutegravir (DTG) combination was priced as Trümeq®; (2) the emtricitabine [FTC] and tenofovir DF (TDF) combination was priced as Truvada®; (3) raltegravir (RAL) was priced as Isentress®; (4) for the regimen tenofovir alafenamide (TAF)/FTC/EVG/cobicistat (COBI) the price of Genvoya® was applied; (5) the regimen comprised of TDF/FTC/riplitivirine (RPV) was priced as Eviplera®; (6) darunavir (DRV) was priced as Prezista®; (7) ritonavir (r) was priced as Norvir®; and (8) for the regimen TDF/FTC/EVG/COBI the price of Striobil® was applied.26 With these prices, the 48 weeks of treatment cost for each regimen is shown in the Table 1.

AE-related costs

The costs of the drugs used to manage AE were estimated based on the drugs’ retail price plus VAT.27 When more than one commercial preparation was available, the least expensive one was chosen. The costs of other resources involved in AE management (emergency room visits, additional visits to the HIV specialist, visits to other specialists, diagnostic tests, and hospital admissions) were averaged due to regional cost variations. In Spain, the health care provision is decentralized at the level of the Autonomous Communities (AC), thus, prices vary by AC. Resources were priced using the official fees in each AC. The cost of each unit of resource was estimated as the average of the prices officially applied to third parties responsible for payment, or to patients not eligible for coverage, of health care services offered by the Departments of Health of each AC (Table 3).

Table 2

<table>
<thead>
<tr>
<th>Initial regimen</th>
<th>Substitution regimens for each initial regimen by reason for change (scientific committee consensus)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Viral failure</td>
</tr>
<tr>
<td>1. ABC/3TC/DTG</td>
<td>6</td>
</tr>
<tr>
<td>2. TDF/FTC + DTG</td>
<td>6</td>
</tr>
<tr>
<td>3. TDF/FTC + RAL</td>
<td>6</td>
</tr>
<tr>
<td>4. TAF/FTC/EVG/COBI</td>
<td>6</td>
</tr>
<tr>
<td>5. TDF/FTC/RPV</td>
<td>6</td>
</tr>
<tr>
<td>6. TDF/FTC + DRV/r</td>
<td>1</td>
</tr>
<tr>
<td>7. TDF/FTC/EVG/COBI</td>
<td>6</td>
</tr>
</tbody>
</table>

ABC: abacavir; COBI: cobicistat; DRV: darunavir; DTG: dolutegravir; EVG: elvitegravir; FTC: emtricitabine; r: ritonavir-boosted; RAL: raltegravir; TAF: tenofovir alafenamide; TDF: tenofovir DF; 3TC: lamivudine.

Table 3
Unit cost of resources.

<table>
<thead>
<tr>
<th>Resource</th>
<th>Euros</th>
<th>Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug resistance studies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conventional</td>
<td>328.00</td>
<td>Study</td>
</tr>
<tr>
<td>Integrase</td>
<td>328.00</td>
<td>Study</td>
</tr>
<tr>
<td>HLA B*5701</td>
<td>151.00</td>
<td>Test</td>
</tr>
<tr>
<td>Visit to specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>First visit</td>
<td>148.66</td>
<td>Visit</td>
</tr>
<tr>
<td>Following visits</td>
<td>87.46</td>
<td>Visit</td>
</tr>
<tr>
<td>Emergency room</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emergency room visit</td>
<td>191.31</td>
<td>Visit</td>
</tr>
<tr>
<td>Hospitalization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital ward admission</td>
<td>559.68</td>
<td>Day</td>
</tr>
<tr>
<td>Diagnostics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ultrasound</td>
<td>75.32</td>
<td>Unit</td>
</tr>
<tr>
<td>Routine blood work</td>
<td>42.49</td>
<td>Unit</td>
</tr>
<tr>
<td>Transaminases</td>
<td>4.34</td>
<td>Unit</td>
</tr>
<tr>
<td>Coagulation</td>
<td>12.53</td>
<td>Unit</td>
</tr>
<tr>
<td>Stool culture</td>
<td>7.81</td>
<td>Unit</td>
</tr>
<tr>
<td>Insulinaemia</td>
<td>24.63</td>
<td>Unit</td>
</tr>
<tr>
<td>Glycemic curve</td>
<td>9.80</td>
<td>Unit</td>
</tr>
<tr>
<td>Treatments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aторvastatine</td>
<td>0.16</td>
<td>10 mg</td>
</tr>
<tr>
<td>Bezafibrate</td>
<td>0.31</td>
<td>400 mg</td>
</tr>
<tr>
<td>Gibencilamide</td>
<td>0.02</td>
<td>5 mg</td>
</tr>
<tr>
<td>Insuline</td>
<td>9.76</td>
<td>300 U</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>0.03</td>
<td>500 mg</td>
</tr>
<tr>
<td>Lornetrazepam</td>
<td>0.07</td>
<td>1 mg</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>0.06</td>
<td>10 mg</td>
</tr>
<tr>
<td>Loperamide</td>
<td>0.31</td>
<td>2 mg</td>
</tr>
<tr>
<td>Loratadine</td>
<td>0.16</td>
<td>10 mg</td>
</tr>
<tr>
<td>Prednisone</td>
<td>0.08</td>
<td>10 mg</td>
</tr>
</tbody>
</table>

Genotypic study of drug resistance and HLA B*5701 testing
Due to lack of official data on the costs of drug resistance studies and HLA B*5701 testing, the costs provided by the Clinic Hospital of Barcelona were used (Table 3). HLA B*5701 testing is considered amortized in 5 years, thus, first-year amortization is 20%.

Definition and calculation of efficiency
Efficiency (cost/efficacy) for each regimen was calculated as the quotient of the cost of initiating treatment with that regimen (numerator) and efficacy (denominator). The result represents the cost of achieving a responder by week 48. The most efficient regimen (least cost per responder) was assigned an efficiency of 1, respect to which the relative efficiency of the rest of the regimens was calculated, being the regimens with small values in the relative efficiency more efficient than those with high values.

Sensitivity analysis
Deterministic sensitivity analysis was performed for each of the models to take into account the underlying uncertainty on efficacy, AE, and costs estimators. These analyses provide the potential range within which the cost/efficacy ratios for each ART regimen would be. To this end, three scenarios were created: base case, most favourable, and least favourable for each initial ART regimen. The base case scenario is defined as the ratio of the central cost estimator (numerator) and the central efficacy estimator (denominator). The most favourable scenario is defined similarly where the numerator is the most favourable cost estimator and the denominator is the most favourable efficacy estimator. Finally, the least favourable scenario uses the least favourable estimators for both costs and efficacy for numerator and denominator, respectively.

The central cost estimator is calculated based on the central estimator of the AE probability and the average costs of AE management, drug resistance studies, and HLA B*5701 testing. The most favourable cost estimator is computed applying the 95% confidence interval (95% CI) lower limit of AE probability, and a 15% cut in the average costs of AE management, drug resistance studies, and HLA B*5701 testing. The least favourable cost estimator is computed applying the 95% CI upper limit of AE probability, and an additional 15% over the average costs of AE management, drug resistance studies, and HLA B*5701 testing. All scenarios include the same cost for each ART regimen since we used official costs that do not involve any uncertainty. Finally, the 95% CI upper and lower limits are used to calculate the most and least favourable estimators of efficacy, respectively.

Software application
Since local cost of a specific hospital may be different to the costs used in the model, a software application that facilitates the assignment of local costs was designed for allowing the calculation of ART costs, regimen initiation costs, efficiency (cost/efficacy), and relative efficiency of initiating treatment with the different regimens at each individual hospital setting. The application is available free of charge at https://dl.dropboxusercontent.com/u/35731022/coste-eficacia-2017/Aplicaci%C3%B3n-TARV-VIH-GESIDA-2017.exe or at http://www.gesida-seimc.org/guias_clinicas.php?mn_MP=406&mn_MS=407.

Results
Fourteen RCTs were included: SINGLE,28 FLAMINGO,29 SPRING-2,30,31 STARTMRK,32 QDMRK,33 ACTG5257,34 GS-US-292-0104/0111,35 ECHO,36 STAR,37,38 ARTEMIS,39 NEAT001/ANRS143,40 GS-US-236-0102,41 GS-US-236-0103,42 and WAVES.43 ACTG525744 and NEAT001/ANRS14340 provide information on outcomes and AE for the week 96. Since our analyses have a time horizon of 48 weeks, we requested the 48 weeks data to the authors. In both cases, formally and confidentially, the authors sent us the required data. With the available scientific evidence, all the PR and AR could be evaluated (Table 1). For regimens that may use ritonavir or COBI as farmacoenhancer (/p), the efficacy and safety of ritonavir and COBI were considered the same.44 Similarly, for regimens that may use TDF or TAF as nucleotide reverse transcriptase inhibitors (TFV) in combination with FTC or FTC/RPV, the efficacy and safety of TDF and TAF were considered the same at 48 weeks.35

Costs of the ART regimens at 48 weeks varied between 6765 and 10,916 Euros, for TFV/FTC/RPV (AR) and TFV/FTC + RAL (PR), respectively (Table 1, Fig. 2B). The cost of initiating ART, in the base case scenario, varied between 6882 Euros for TFV/FTC/RPV (AR) and 10,894 Euros for TFV/FTC + RAL (PR). Within the most favourable scenario, costs varied between 6851 and 10,888 Euros for TFV/FTC/RPV (AR) and TFV/FTC + RAL (PR), respectively. Within the least favourable scenario, costs fluctuated between 6917 and 10,904 Euros for TFV/FTC/RPV (AR) and TFV/FTC + RAL (PR) (Table 4 and Fig. 2A and B).

The efficacy in base case scenario ranged between 0.82 (82% response rate at 48 weeks) for TFV/FTC + DRV/p (AR) and 0.92 for TAF/FTC/EVG/COBI (PR). Within the most favourable scenario, the efficacy varied between 0.84 for TFV/FTC + DRV/p (AR) and 0.94 for TAF/FTC/EVG/COBI (PR). The least favourable scenario shows a variation in efficacy ranging from 0.80 for TFV/FTC + DRV/p (AR) and 0.91 for TAF/FTC/EVG/COBI (PR) (Table 4 and Fig. 2A).

The efficacy (cost/efficacy), in the base case scenario, varied between 7923 and 12,765 Euros per responder for ABC/3TC/DG (PR) and TFV/FTC + RAL (PR), respectively. The efficiency values, in the most favourable scenario, ranged between 7652 and 12,496.

Euros per responder for ABC/3TC/DTG (PR) and TFV/FTC + RAL (PR), respectively. Within the least favourable scenario, these same estimates varied between 8217 and 13,048 Euros per responder for ABC/3TC/DTG (PR) and TFV/FTC + RAL (PR), respectively. When initiating ART with the regimen TFV/FTC + RAL (PR), each responder was 61.0% more expensive than with the regimen ABC/3TC/DTG (PR) if using the base case scenario, 63.3% more expensive in the most favourable scenario, and 58.8% more expensive in the least favourable scenario.

### Discussion

The GESIDA/PNS panel stratified the recommended regimens in PR, AR and OR according to reasons widely justified and discussed in the original report. of the ART regimens recommended by GESIDA/PNS in their 2017 consensus paper as PR or AR for naïve patients, TFV/FTC/RPV (AR) emerged as the least expensive whether considering the ART cost alone or considering all the additional costs derived from the decision of initiating treatment with an ART regimen (AE management, drug resistance tests, HLA B*5701 test, and regimen change). However, the most efficient was ABC/3TC/DTG (PR) because of its higher efficacy and similar cost. Some regimens present a high efficacy but are less efficient due to their high cost (e.g., TDF/FTC/EVG/CObi).

The cost of initiating a treatment with a regimen is the real costs to the NHS because it includes ART costs and the costs of the consequences (e.g., AE management or switching the regimen); whereas for the hospital’s pharmacy the cost consists of only the ART. The ratio cost/efficacy represents the NHS cost of achieving one responder, at 48 weeks in our case. In certain cases, the physician and/or

![Fig. 2. Representation of the base case scenario. (A) Cost: cost of initiating a regimen including all potential consequences of initiating ART with that regimen (Adverse effects [AE] and changes to other regimens) that may occur within 48 weeks. Efficacy: proportion of patients with undetectable plasma viral load (<50 copies of HIV-RNA/mL) at 48 weeks. The slope between the y-intercept and the coordinates for each regimen represents the efficiency (cost/efficacy). The slope reflects the cost of achieving one responder by week 48 from the payer perspective: The National Health Service (NHS). (B) ART Cost: Drug costs for each regimen for 48 weeks (labouratory sale price [LSP] + 4% VAT – 7.5% reduction). Cost of initiating ART: cost of initiating a regimen including all potential consequences of initiating ART with that regimen (Adverse effects [AE] and changes to other regimens) that may occur within 48 weeks. Cost per Responder: Cost of achieving one responder (<50 copies of HIV-RNA per mL of plasma) by week 48 from the payer (NHS) perspective, calculated as the cost of initiating ART divided by its efficacy. ABC: abacavir; Cobi: cobicistat; DRV: darunavir; DTG: dolutegravir; Evg: elvitegravir; FTC: emtricitabine; p: ritonavir-boosted or cobicistat-boosted; RAL: raltegravir; TAF: tenofovir alafenamide; TDF: tenofovir DF; TVF: TDF or TAF; 3TC: lamivudine. PR: regimen designated as “Preferred” by the expert panel of GESIDA and the 2016 AIDS National Plan. AR: Regimen designated as “Alternative” by the expert panel of GESIDA and the 2016 AIDS National Plan.

<table>
<thead>
<tr>
<th>Initial regimen</th>
<th>Baseline scenario</th>
<th>Most favourable scenario</th>
<th>Least favourable scenario</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cost (Euros)</td>
<td>Efficacy</td>
<td>Relative C/E</td>
</tr>
<tr>
<td>ABC/3TC/DTG (PR)</td>
<td>6941</td>
<td>0.88</td>
<td>7923</td>
</tr>
<tr>
<td>TFV/FTC + DTG (PR)</td>
<td>9275</td>
<td>0.89</td>
<td>10,377</td>
</tr>
<tr>
<td>TFV/FTC + RAL (PR)</td>
<td>10,894</td>
<td>0.85</td>
<td>12,765</td>
</tr>
<tr>
<td>TAF/FTC/EVG/CObi (PR)</td>
<td>7644</td>
<td>0.82</td>
<td>8275</td>
</tr>
<tr>
<td>TFV/FTC/RPV (AR)</td>
<td>6882</td>
<td>0.84</td>
<td>8148</td>
</tr>
<tr>
<td>TFV/FTC + DRV/p (AR)</td>
<td>8866</td>
<td>0.82</td>
<td>10,803</td>
</tr>
<tr>
<td>TDF/FTC + RAL (PR)</td>
<td>9151</td>
<td>0.82</td>
<td>10,262</td>
</tr>
</tbody>
</table>

ABC: abacavir; Cobi: cobicistat; DRV: darunavir; DTG: dolutegravir; Evg: elvitegravir; FTC: emtricitabine; p: ritonavir-boosted or cobicistat-boosted; RAL: raltegravir; TAF: tenofovir alafenamide; TDF: tenofovir DF; TVF: TDF or TAF; 3TC: lamivudine. PR: regimen designated as “Preferred” by the expert panel of GESIDA and the 2016 AIDS National Plan. AR: Regimen designated as “Alternative” by the expert panel of GESIDA and the 2016 AIDS National Plan.

The cost of initiating a regimen including all potential consequences of deciding to initiate ART with that regimen (adverse effects and changes to other regimens) may occur within 48 weeks.

Efficiency or cost/efficacy. Cost (Euros) of achieving one responder for the NHS (<50 copies of RNA of HIV per mL of plasma by week 48; ITT-E missing or NC = failure).

To calculate the relative C/E, a value of 1 was assigned to the most efficient regimen (ABC/3TC/DTG).

Efficacy data and costs based in regimen with TDF.

Efficacy data based in regimen with ritonavir.
the patient may prefer a triple therapy regimen based on a non-nucleoside, a PI/r, or an integrase inhibitor, or even a dual therapy, for clinical reasons or personal preferences. In such cases, the costs of initiating treatment, its efficacy, and the cost/efficacy ratio would have to be considered within each of these regimens and might not necessarily be the major driver in the decision making process.

For all regimens, the main cost of initiating treatment is the ART due to its high price. In contrast, the costs related to managing AE are low since only a very small percentage of patients present AE and the involved costs are low.

The study results should be interpreted in the context of its limitations. A potential limitation is that the analyses are based on RCTs performed in different countries, during different periods of time, with different inclusion and exclusion criteria. Thus, results may have differed if all regimens had been administered in similar populations and time periods. In fact, more recent studies include lower percentages of patients with poor prognosis, i.e., those with low CD4 counts (<100/200 cells/μL) and high plasma viral load (>100,000 copies/mL). This leads to results with higher levels of efficacy than those reported in previous studies and may offer an advantage to drugs assessed recently for the first time. In addition, there are drugs with restricted use. For instance, RPV is only approved for individuals with baseline plasma viral loads <100,000 copies/mL, and TDF/FTC/EVG/COBI is only approved for patients with estimated glomerular filtration rate > 70 mL/min. RPV efficacy results in patients with plasma viral load <100,000 copies/mL are better than the average efficacy from the RCTs included in this analysis. However, these studies included patients similar to those participating in studies of the other drugs, thus, efficacy data rather to comparable patient groups.

Another limitation is that some RCTs do not specify which AE were ART-related, such lack of information was completed with the experts’ opinion. Similarly, for lack of other scientific evidence, i.e., resources needed for AE management and the substitution regimens used when the initial regimen was suspended were estimated based on experts’ opinion. At the time of writing the manuscript, the combinations TAF/FTC and TAF/FTC/RPV are not commercialized in Spain and, consequently, their billing prices are not available. Nevertheless, the TAF/FTC notified price has been made public recently and coincides with the TDF/FTC notified price. In consequence, to assume that the TAF/FTC and TAF/FTC/RPV billing prices will be the same as TDF/FTC and TDF/FTC/RPV, respectively, seems the most reasonable.

Additionally, although the study’s methodology ensures agreement at a national level, calculations may differ in other countries. Regimens’ efficacy was evaluated using the ITT-E analytical approach assigning missing or incomplete follow-ups as failures (“missing or non-completer = failure”). This method of evaluation may not coincide with the main end-point in some of the studies, though the data published in the reports do allow for the necessary calculations. In other words, results may have differed if other analytical methods of measuring efficacy had been used instead. Also, when more than one RCT assessed the same regimen, a metaanalysis could not be performed because of the absence of a common comparator. Finally, another limitation would be that these findings are applicable only to Spain and taking into account the Spanish official drug prices in January 2017, not considering potential local discounts even when they could be substantial and not uncommon as in the case of RAL. Thus, results should be interpreted cautiously especially in environments where prices differ substantially from the Spanish average.

Major strengths of this study include the use of the best scientific evidence available and the sensitivity analyses performed to best capture the underlying uncertainty in costs and outcomes. Further, the models use efficacy estimators, with universal validity, which, added to the fact that the methodology is applicable to any environment, would make the results valid in other contexts as long as local costs could be entered into the models.

In order to facilitate the use of this methodology in other centers or countries with different ART- or HIV management-related costs or to take into account the potential future use of generic drugs, a software application was developed and made available free of charge at https://dl.dropboxusercontent.com/u/35731022/costefficacia-2017/Aplicaci%C3%B3n-TARV-VIH-GESIDA-2017.exe or at http://www.gesida-seimc.org/guias_clinicas.php?mn_MP=406&mn_MS=407. This application allows the calculations of ART costs, initiating ART costs, efficiency (cost/efficacy), and the relative efficiency of initiating treatment with the different regimens based on local costs of the medicines and the management of side effects. This application will aid any centre interested in computing its own estimates based on the model developed here.

The ideal study design to determine ART efficiency in regular clinical practice would be a prospective cohort cost/effectiveness study with a long follow-up period, but these studies are unlikely to be carried out. When lacking such studies, cost/effectiveness models provide a very useful tool to examine costs and ART efficiency based on the best scientific evidence available.

Current study findings are relevant because the mission of any health care system is to maximize the population’s health outcomes in a context of inherently limited resources. In such context, guaranteeing the system’s sustainability requires an efficient use of the limited resources.

At the patient–physician level, the drug efficiency is an important characteristic of therapy but not necessary the most important driver when choosing an antiretroviral combination as initial therapy, because other features must be taken into consideration as efficacy, tolerability, safety, convenience, drug-drug interactions and resistance profile. So, results might be cautiously interpreted, as the most efficient combination may not be the best one. For this reason, periodic economic evaluation studies, such as this one, have the potential of facilitating the decision making process of health professionals, managers, and political decision-makers in the field of HIV-infection management.

Conflict of interest

Antonio Rivero has received consultancy fees from Abbott Laboratories, Bristol-Myers Squibb, Boehringer Ingelheim, ViiV Healthcare, Gilead Sciences, GlaxoSmithKline, Janssen and Roche Pharmaceuticals, and speaker fees from Abbott Laboratories, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, ViiV Healthcare, Janssen, Merck Sharp & Dohme and Roche Pharmaceuticals.

José Antonio Pérez-Molina has received consultancy fees from Bristol-Myers Squibb, ViiV Healthcare, and Gilead Sciences, and speaker fees from Bristol-Myers Squibb, ViiV Healthcare, and Merck Sharp & Dohme.

Antonio Javier Blasco has no potential conflicts of interest related to this study.

José Ramón Arribas receives advisory fees, speaker’s fees, or grant support from ViiV Healthcare, Janssen, Gilead Sciences and Merck Sharp & Dohme.

Victor Asensi has received consultancy and speaker fees or grant support from Janssen Pharmaceuticals Abbvie, ViiV Healthcare, Gilead Sciences, and Merck Sharp & Dohme.

Manuel Crespo has received consultancy fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, Janssen, and ViiV Healthcare. Dr Crespo has also received research grants from AbbVie, Pfizer, Gilead Sciences and ViiV Healthcare.

Pere Domingo has received honoraria for consultancy from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, Janssen, and ViIV Healthcare. He has also received research grants (money for Institution) from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Pfizer Inc and ViIV Healthcare. He had also received honoraria for speech from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme, Gilead Sciences, Janssen, and ViIV Healthcare. Dr. Domingo is recipient of a grant from the Programa de Intensificación from FIS in the year 2013 (INTI 12/383).

José Antonio Iribarren has disclosed that he has served as an advisor or consultant for Abbvie, Gilead and Janssen; grant support from Abbvie, BMS, MSD, Basque Government, FIPSE and FISS, and support to attendance to conferences from Abbvie, BMS, Gilead, Janssen, MSD, and ViIV Healthcare.

Pablo Lázaro has no potential conflicts of interest related to this study.

José López-Aldeguer has received consultancy and speaker fees from Abbott Laboratories, ViIV Healthcare, Gilead Sciences, Janssen Pharmaceuticals and Merck Sharp & Dohme.

Fernando Lozano has disclosed that he has served as an advisor or consultant for Abbvie, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Janssen, Merck-Sharp & Dohme, Roche Pharmaceuticals and ViIV Healthcare; and has also served on the speaker’s bureaus for, as well as received support for educational activities from Abbvie, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp & Dohme, Roche Pharmaceuticals and ViIV Healthcare.

Esteban Martínez has received honoraria as consultant for Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Theratechnologies y ViIV Healthcare; he has received grants for research from Merck Sharp & Dohme, and he has received support for educational activities from Abbvie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, MerckSharp & Dohme, y ViIV Healthcare.

Santiago Moreno has been involved in speaking activities and has received grants for research from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Glaxo Smith Kline, Janssen Cilag, Merck Sharp & Dohme, Pfizer, Roche, and Schering Plough.

Rosario Palacios receives advisory fees, speaker’s fees, or grant support from ViIV Healthcare, Janssen, Bristol-Myers Squibb, Gilead Sciences, and Merck Sharp & Dohme.

Juan Antonio Pineda has received honoraria as consultant for Abbvie, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen Cilag and Merck Sharp & Dohme; has received grants for research from Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen Cilag, Merck Sharp & Dohme, Roche Pharma and ViIV Healthcare; and speaker fees from Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen Cilag, Merck Sharp & Dohme, Roche Pharma and ViIV Healthcare.

Federico Pulido receives advisory fees, speaker’s fees, or grant support from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp & Dohme and ViIV Healthcare.

Rafael Rubio reports grants from Abbott and Janssen, and payment for lectures from Abbott, Bristol-Myers Squibb, ViIV, Gilead, Janssen, and Merck Sharp & Dohme.

Jesús Santos has received honoraria as consultant for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen Cilag and Merck Sharp & Dohme; has received grants for research from Gilead Sciences, GlaxoSmithKline, Janssen Cilag and speaker fees from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen Cilag, Merck Sharp & Dohme and ViIV Healthcare.

Javier de la Torre has received consultancy fees from ViIV Healthcare, Gilead Sciences; and speaker fees from Abbott Laboratories, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, ViIV Healthcare, Janssen, Merck Sharp & Dohme and Roche Pharmaceuticals.

Montserrat Tuset has received grants from Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, and Janssen and speaker fees from Janssen, Merck Sharp & Dohme, and participating in Advisory Boards from ViIV Healthcare.

Josep M. Gatell has received honoraria for speaking or participating in Advisory Boards and/or research grants (his institution) from Merck Sharp & Dohme, Gilead Sciences, Janssen and ViIV Healthcare.

Acknowledgements

Support and funding for this study come from Grupo de Estudio de SIDA (GESIDA), Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) (AIDS Study Group, Spanish Society for Infectious Diseases and Clinical Microbiology). The study benefitted from the scientific sponsorship and support of the Red de Investigación en SIDA (AIDS Research Network) (RIS; RD06/0006 and RD12/0017).

We thank the NEAT001/ANRS143 study researchers Elizabeth C George, François Raffi, Christine Schwimmer, Abdel G Babiker, and Cédrick Wallet for providing us with unpublished data regarding the outcomes and adverse events at the 48 week without the inclusion of the NEAT001/ANRS143 study would be impossible.

We thank the ACTG A5257 researchers Lumine H. Na, Jeffrey L. Lennox, Daniel R. Kiritzkies, and Heather J. Ribaudo for providing us with unpublished data regarding the outcomes and adverse events at the 48 week without which the inclusion of the ACTG A5257 study would be impossible.

References


